Here, we describe an anti‐BAG3 humanized mAb able to block BAG3 activity and PDAC tumor growth, providing evidence that BAG3‐ H2L4 humanized antibody is a potential candidate for BAG3‐based targeted therapy in the clinical setting. This evidence concerns the gene BAG3 and neoplasm.